# A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

> **NCT01428297** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers
- Atopic Dermatitis
- Netherton Syndrome

## Interventions

- **DRUG:** BPR277 ointment (controlled application)
- **DRUG:** Placebo (Vehicle)
- **DRUG:** BPR277 ointment
- **DRUG:** Placebo (Vehicle)
- **DRUG:** BPR277
- **DRUG:** Placebo (Vehicle)

## Key facts

- **NCT ID:** NCT01428297
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428297, "A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01428297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*